Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DTIL NASDAQ:FDMT NASDAQ:NLTX NASDAQ:NMRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDTILPrecision BioSciences$4.61-7.8%$4.80$3.61▼$10.68$58.94M1.6159,590 shs368,830 shsFDMT4D Molecular Therapeutics$6.81-3.7%$5.70$2.23▼$17.41$318.04M2.86617,578 shs517,375 shsNLTXNeoleukin Therapeutics$19.00-5.4%$20.74$2.03▼$14.36$178.56M1.1150,104 shs123,069 shsNMRANeumora Therapeutics$1.62-2.4%$1.65$0.61▼$17.19$262.35M2.91361,367 shs440,408 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDTILPrecision BioSciences-7.80%-9.07%-1.71%-5.92%-56.10%FDMT4D Molecular Therapeutics-3.68%-6.33%+2.10%+55.13%-56.68%NLTXNeoleukin Therapeutics+7.96%+2.40%+4.47%+1.62%-48.96%NMRANeumora Therapeutics-2.41%-3.57%+3.85%+91.83%-85.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDTILPrecision BioSciences$4.61-7.8%$4.80$3.61▼$10.68$58.94M1.6159,590 shs368,830 shsFDMT4D Molecular Therapeutics$6.81-3.7%$5.70$2.23▼$17.41$318.04M2.86617,578 shs517,375 shsNLTXNeoleukin Therapeutics$19.00-5.4%$20.74$2.03▼$14.36$178.56M1.1150,104 shs123,069 shsNMRANeumora Therapeutics$1.62-2.4%$1.65$0.61▼$17.19$262.35M2.91361,367 shs440,408 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDTILPrecision BioSciences-7.80%-9.07%-1.71%-5.92%-56.10%FDMT4D Molecular Therapeutics-3.68%-6.33%+2.10%+55.13%-56.68%NLTXNeoleukin Therapeutics+7.96%+2.40%+4.47%+1.62%-48.96%NMRANeumora Therapeutics-2.41%-3.57%+3.85%+91.83%-85.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDTILPrecision BioSciences 3.00Buy$47.00919.52% UpsideFDMT4D Molecular Therapeutics 2.64Moderate Buy$30.40346.40% UpsideNLTXNeoleukin Therapeutics 0.00N/AN/AN/ANMRANeumora Therapeutics 2.22Hold$7.14340.92% UpsideCurrent Analyst Ratings BreakdownLatest DTIL, NMRA, FDMT, and NLTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/30/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating8/14/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating8/12/2025FDMT4D Molecular TherapeuticsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$44.00 ➝ $38.008/12/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/1/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.007/29/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating7/16/2025NMRANeumora TherapeuticsMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$4.00 ➝ $5.007/12/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating7/3/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.006/27/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDTILPrecision BioSciences$1.26M43.09N/AN/A$6.87 per share0.67FDMT4D Molecular Therapeutics$33K9,637.59N/AN/A$11.05 per share0.62NLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/ANMRANeumora TherapeuticsN/AN/AN/AN/A$1.78 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDTILPrecision BioSciences$7.17M-$8.81N/AN/AN/A-6,205.79%-176.47%-69.05%11/3/2025 (Estimated)FDMT4D Molecular Therapeutics-$160.87M-$3.53N/AN/AN/A-594,375.81%-40.15%-36.43%11/12/2025 (Estimated)NLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/ANMRANeumora Therapeutics-$243.79M-$1.57N/AN/AN/AN/A-98.95%-87.68%11/11/2025 (Estimated)Latest DTIL, NMRA, FDMT, and NLTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025FDMT4D Molecular Therapeutics-$0.88-$0.98-$0.10-$0.98$0.52 million$0.01 million8/7/2025Q2 2025DTILPrecision BioSciences-$0.09-$2.13-$2.04-$2.13$6.27 million$0.02 million8/6/2025Q2 2025NMRANeumora Therapeutics-$0.38-$0.33+$0.05-$0.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDTILPrecision BioSciencesN/AN/AN/AN/AN/AFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/ANMRANeumora TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDTILPrecision BioSciences0.665.185.18FDMT4D Molecular TherapeuticsN/A8.758.75NLTXNeoleukin TherapeuticsN/A15.3315.33NMRANeumora Therapeutics0.1110.5410.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDTILPrecision BioSciences37.99%FDMT4D Molecular Therapeutics99.27%NLTXNeoleukin Therapeutics52.37%NMRANeumora Therapeutics47.65%Insider OwnershipCompanyInsider OwnershipDTILPrecision BioSciences4.50%FDMT4D Molecular Therapeutics9.60%NLTXNeoleukin Therapeutics1.58%NMRANeumora Therapeutics26.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDTILPrecision BioSciences20011.79 million11.26 millionNo DataFDMT4D Molecular Therapeutics12046.70 million42.22 millionOptionableNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataNMRANeumora Therapeutics108161.95 million118.54 millionOptionableDTIL, NMRA, FDMT, and NLTX HeadlinesRecent News About These CompaniesNeumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $7.14 Average Price Target from AnalystsSeptember 12 at 2:33 AM | americanbankingnews.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Hold" by AnalystsSeptember 11 at 5:13 AM | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Short Interest Down 26.3% in AugustSeptember 10 at 6:40 PM | marketbeat.comNuveen LLC Takes $221,000 Position in Neumora Therapeutics, Inc. $NMRASeptember 8, 2025 | marketbeat.comGraham Capital Management L.P. Has $1.16 Million Holdings in Neumora Therapeutics, Inc. $NMRASeptember 6, 2025 | marketbeat.comNeumora Therapeutics to Participate in Upcoming Conferences in SeptemberSeptember 2, 2025 | globenewswire.comT. Rowe Price Investment Management Inc. Sells 2,899,770 Shares of Neumora Therapeutics, Inc. $NMRAAugust 27, 2025 | marketbeat.comNeumora Therapeutics Initiates Phase 1 Study for Schizophrenia Drug NMRA-861August 20, 2025 | msn.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of "Hold" by AnalystsAugust 16, 2025 | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Bought by XTX Topco LtdAugust 14, 2025 | marketbeat.comNeumora Therapeutics, Inc.: Promising Potential in Obesity Therapeutics with NMRA-215August 7, 2025 | tipranks.comNeumora outlines six upcoming clinical catalysts and prioritizes obesity program with NMRA-215August 7, 2025 | msn.comNeumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call TranscriptAugust 7, 2025 | seekingalpha.comNeumora Therapeutics Reports Q2 2025 Financial ResultsAugust 7, 2025 | tipranks.comNeumora Therapeutics reports Q2 EPS (33c), consensus (37c)August 6, 2025 | msn.comNeumora (NMRA) Q2 Loss Improves 10%August 6, 2025 | aol.comANeumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 6, 2025 | globenewswire.comMizuho Raises Price Target for Neumora (NMRA), Keeps Outperform RatingJuly 30, 2025 | msn.com5 Alzheimer’s Readouts To WatchJuly 28, 2025 | biospace.comBNeumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025July 23, 2025 | globenewswire.comMizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform RatingJuly 20, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDTIL, NMRA, FDMT, and NLTX Company DescriptionsPrecision BioSciences NASDAQ:DTIL$4.61 -0.39 (-7.80%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$4.64 +0.03 (+0.65%) As of 09/12/2025 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.4D Molecular Therapeutics NASDAQ:FDMT$6.81 -0.26 (-3.68%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$6.81 0.00 (0.00%) As of 09/12/2025 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.Neoleukin Therapeutics NASDAQ:NLTX$19.00 -1.08 (-5.38%) As of 09/12/2025Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Neumora Therapeutics NASDAQ:NMRA$1.62 -0.04 (-2.41%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.62 +0.00 (+0.31%) As of 09/12/2025 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
